| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
10,710,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cingulate is a holding company. Co. is engaged in clinical stage biopharmaceutical focused on the development of products using its key Precision Timed Release drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Co.'s two proprietary stimulant medications: CTx-1301 (dexmethylphenidate) and CTx-1302, are being developed for the treatment of ADHD intended for all patient segments: children (ages six to 12), adolescents (ages 13 to 17), and adults (ages18 plus).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,828,155 |
1,984,376 |
| Total Buy Value |
$0 |
$0 |
$1,003,350 |
$1,199,767 |
| Total People Bought |
0 |
0 |
2 |
5 |
| Total Buy Transactions |
0 |
0 |
2 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Callahan Jennifer L. |
SVP and CFO |
• – – |
2022-03-15 |
4 |
B |
$27.10 |
$1,491 |
D/D |
55 |
2,333 |
2.66 |
- |
|
| Givens Gregg Wm |
Director |
– • – |
2022-03-15 |
4 |
B |
$1.37 |
$16,493 |
I/I |
12,000 |
10,000 |
2.1 |
- |
|
| Givens Gregg Wm |
Director |
– • – |
2022-03-15 |
4 |
B |
$1.38 |
$37,338 |
D/D |
27,000 |
69,318 |
2.39 |
- |
|
| Givens Gregg Wm |
Director |
– • – |
2022-03-14 |
4 |
B |
$1.29 |
$23,288 |
I/I |
18,000 |
6,000 |
2.1 |
- |
|
| Givens Gregg Wm |
Director |
– • – |
2022-03-14 |
4 |
B |
$1.32 |
$11,866 |
D/D |
9,000 |
42,318 |
2.39 |
- |
|
| Van Horn Louis G |
EVP and CFO |
• – – |
2022-03-14 |
4 |
B |
$1.34 |
$20,045 |
D/D |
15,000 |
15,000 |
2.74 |
- |
|
| Medeiros Curtis |
Director |
– • – |
2022-03-14 |
4 |
B |
$1.41 |
$24,764 |
D/D |
17,532 |
17,532 |
2.39 |
- |
|
| Gilgallon Craig S. |
EVP & General Counsel |
• – – |
2022-03-14 |
4 |
B |
$1.38 |
$8,227 |
D/D |
5,975 |
5,975 |
2.74 |
- |
|
| Callahan Jennifer L. |
Corporate Controller |
• – – |
2022-03-14 |
4 |
B |
$1.46 |
$17,494 |
D/D |
12,000 |
16,543 |
2.74 |
- |
|
| Hargroves Thomas Jeffrey |
Director |
– • – |
2021-12-10 |
4 |
B |
$0.00 |
$0 |
D/D |
8,300 |
8,300 |
2.31 |
- |
|
| Schaffer Shane J. |
Chief Executive Officer |
• • – |
2021-12-10 |
4 |
B |
$0.00 |
$0 |
D/D |
16,500 |
16,500 |
2.73 |
- |
|
| Werth Peter J. |
Director |
– • – |
2021-12-10 |
4 |
B |
$0.00 |
$0 |
I/I |
8,300 |
844,731 |
2.02 |
- |
|
| Givens Gregg Wm |
Director |
– • – |
2021-12-10 |
4 |
B |
$0.00 |
$0 |
D/D |
16,500 |
33,318 |
2.31 |
- |
|
| Fountainhead Shrugged, Llc |
10% Owner |
– – • |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
807,828 |
|
- |
|
| Myers Laurie |
EVP & Chief Operating OfficerO |
• – – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,963 |
|
- |
|
| Werth Peter J. |
Director |
– • • |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
836,431 |
|
- |
|
| Werth Peter J. |
Director |
– • • |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,849 |
|
- |
|
| Conroy Jeffrey X |
Director |
– • – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,949 |
|
- |
|
| Callahan Jennifer L. |
Corporate ControllerOfficer |
• – – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,543 |
|
- |
|
| Brams Matthew |
EVP & Chief Medical OfficerOff |
• – – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
650,240 |
|
- |
|
| Van Horn Louis G |
EVP & Chief Financial OfficerO |
• – – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
141,606 |
|
- |
|
| Givens Gregg Wm |
Director |
– • – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,818 |
|
- |
|
| Gilgallon Craig S. |
EVP & General CounselOfficer |
• – – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
185,296 |
|
- |
|
| Gallagher Patrick Joseph |
Director |
– • – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
68,358 |
|
- |
|
| Silva Raul R. |
EVP & Chief Science OfficerOff |
• – – |
2021-12-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
467,232 |
|
- |
|
52 Records found
|
|
Page 2 of 3 |
|
|
